New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:51 EDTISRIsoRay advances strongly for a second session, levels to watch
Shares advanced strongly on Wednesday and in early trading today are up over 35% to $3.45. At that price next resistance is at $3.76. Support is at $2.99. On a long term chart the strong move up constitutes a long base breakout which are typically bullish for share price on a sustainable basis. The $2 area had been the top of the range extending back to 2009.
News For ISR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
08:37 EDTISRIsoRay selected by Chicago prostate cancer center for use in study
IsoRay announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy. Focal therapy is treatment directed solely at the malignancy and its immediate surrounding tissue, rather than the entire gland or organ that is involved. The goal of focal therapy for prostate cancer is to eliminate the targeted cancer while sparing men the side effects that often come with whole gland treatment.
June 23, 2015
08:37 EDTISRIsoRay intends to 'vigorously' defend litigation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use